The average one-year price target for AstraZeneca PLC - Depositary Receipt (NasdaqGS:AZN) has been revised to $202.76 / share ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) announced on January 30 that it is bolstering its weight management portfolio ...

Investing.com -- AstraZeneca PLC (ST:AZN) stock fell 1.5% in Tuesday morning trade after the U.S. Food and Drug Administration rejected the company’s initial submission for its Saphnelo lupus drug in ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best healthcare stocks to buy for 2026. On January 29, AstraZeneca announced a $15 billion investment in China through 2030 to expand manufacturing and R&D, ...

February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...

AstraZeneca PLC research and ratings by Barron's. View AZN revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

CSPC Pharmaceutical Group Ltd (HK:1093) announced a major strategic partnership with AstraZeneca PLC (ST:AZN), marking one of ...

The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023. Early this morning, AstraZeneca shared ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi, in combination with chemotherapy, has been recommended for approval in the EU for the treatment of adult patients with resectable, early-stage ...

On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of ...

AstraZeneca PLC ADR stock grades by Barron's. View AZN fundamental and sentiment analysis powered by MarketGrader.